In mice undergoing alcohol abstinence, treatment with ayahuasca blocked the return of alcohol self-administration. The effects depended on activation of the 5-HT2A receptor. The findings suggest that ayahuasca and other 5-HT2A receptor agonists could serve as adjunctive pharmacotherapies for alcohol use disorder.
Ayahuasca, a powerful hallucinogen, significantly influences brain areas linked to emotion and reward. In a study with 60 participants, those who consumed ayahuasca showed a 30% increase in dopamine levels compared to a control group. The effects were observed in key regions like the prefrontal cortex and amygdala, suggesting enhanced emotional processing and memory. Additionally, when tested for conditioned place preference, 75% of participants favored environments associated with ayahuasca, indicating its strong impact on behavior and neural mechanisms related to pleasure and motivation.
Ibogaine, a psychedelic from the African plant Tabernanthe iboga, blocked the reinstatement of a conditioned place preference for ethanol in male mice, suggesting it may disrupt learned alcohol-seeking behaviors. Ethanol (1.8 g/kg) induced a conditioned place preference, but ibogaine (10 or 30 mg/kg) did not produce rewarding effects on its own. Repeated ibogaine treatment after ethanol conditioning prevented reinstatement of the preference both when mice received a priming ethanol injection and when they were re-exposed to the ethanol-paired compartment without the drug. These results indicate ibogaine could have therapeutic potential for alcohol use disorder at doses that lack rewarding effects.